PDCD1 and colorectal carcinoma: In 2015 and 2016, the American Society of Clinical Oncology (ASCO) published clinical trials of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors, pembrolizumab, and nivolumab in the treatment of advanced CRC.